Passive Transfer of Diabetes from BB/W to Wistar-Furth Rats

Steven B. Koevary, Debora E. Williams, R. Michael Williams, and William L. Chick
Biochemistry and Medicine Departments, University of Massachusetts Medical Center, Worcester, Massachusetts 01605; and Department of Medicine, Northwestern University, Chicago, Illinois 60611

Abstract
Autoimmune diabetes can be transferred to young, diabetes prone BB/W rats by injecting them intraperitoneally with concanavalin A (Con A)-treated spleen cells from acute diabetic BB/W donors. This study describes the transfer of diabetes to the normal Wistar-Furth strain of rats using a similar procedure. For the successful transfer of diabetes it was necessary to immunosuppress recipient animals with a single intraperitoneal injection of cyclophosphamide 24-48 h before administering Con A-stimulated spleen cells from acute diabetic BB/W rats. Of 68 Wistar-Furth rats immunosuppressed with a dose of 100-150 mg cyclophosphamide/kg body wt, 10 (15%) became diabetic. None of the control rats receiving either Con A-stimulated Wistar-Furth spleen cells (n = 28), freshly isolated BB/W spleen cells (n = 14), or fresh RPMI medium (n = 11) became diabetic. These data indicate that diabetes can be transferred from BB/W to Wistar-Furth rats. In addition, they support the hypothesis that cell-mediated immune processes are involved in the development of insulin-dependent diabetes and rule out any absolute requirement for BB-derived genes in the target pancreatic beta cells.

Introduction
Spontaneous diabetes in the nonobese BB/W rat is similar to human Type I disease (1). It develops in animals of both sexes between ~60 and 120 d of age, and is characterized by the abrupt onset of severe hyperglycemia requiring insulin therapy. Many studies indicate an autoimmune etiology (2-6). An important characteristic finding is insulinitis, suggesting cell-mediated autoimmunity plays a role in the destruction of beta cells. This possibility is supported by the fact that antilymphocyte serum (7), neonatal thymectomy (8), and bone marrow transplantation (9) either reduce the incidence of or prevent diabetes.

Development of a means for passive transfer of diabetes using BB/W cells would provide an important model for investigating the pathogenesis of autoimmune diabetes. Furthermore, it would support the hypothesis that cell-mediated immunity plays a role in the pathogenesis of diabetes in these animals. In this regard, previous studies describe passive transfer of insulitis from acute diabetic BB rats to immunologically deficient athymic nude mice using spleen and peripheral blood cells (10). However, these studies have proved difficult to repeat (11). Passive transfer of insulitis from BB to X-irradiated BB recipients has also been briefly reported in a few animals (12).

Interestingly, transfer of another autoimmune disease in rodents, experimental allergic encephalomyelitis, is significantly enhanced by culturing donor cells from affected animals with the T cell mitogen concanavalin A (Con A) (13). Since clearcut transfer of severe diabetes was not possible using freshly isolated cells, we conducted experiments in which spleen cells from acute diabetic BB/W donors were first cultured with Con A. When these cells were injected intravenously into young diabetes prone BB/W recipients, 60-90% developed severe insulitis and hyperglycemia within an average of 12 d (14).

In this study, we undertook to determine whether diabetes can be transferred to a normal strain of rat. This would provide data on whether beta cells from rats that do not normally develop diabetes can be recognized and selectively damaged by transfer of immune cells from an acute diabetic BB/W animal. Since the possibility exists that killing of beta cells through passive transfer involves donor immune cells restricted to the major histocompatibility complex (MHC) (i.e., they must first recognize self-MHC on the beta cells for killing to occur), we chose Wistar-Furth rats (MHC RT1") as our recipients because they share MHC identity with BB rats (15). Because our earlier data suggested an inability to transfer into untreated Wistar-Furth rats, recipients were immunosuppressed with cyclophosphamide. Immunosuppression may be necessary to prevent rejection or suppression of donor cells due to differences in minor histocompatibility antigens.

Methods
Donor BB/W rats. BB/W rats were obtained from the University of Massachusetts Medical School breeding facility (Worcester, MA). The frequency of spontaneous diabetes averages 40-60% between 60 and 120 d of age. The disease occurs with equal frequency in both males and females. Donors with acute diabetes were produced by random matings between diabetic males and nondiabetic females. Glycosuria in male and female rats was determined twice a week with Testape (El Lilly Co., Indianapolis, IN), and hyperglycemia was verified by determining the plasma glucose concentration with a glucose analyzer (Beckman Instruments, Inc., Fullerton, CA). Con A-stimulated spleen cells from 34 male and female acute diabetic rats between 57 and 111 d of age were used within 4 d of onset of hyperglycemia. Freshly isolated spleen cells (not stimulated with Con A) from seven acute diabetic rats were used as control donor cells. Additional controls included spleen cells derived from 14 male and female Wistar-Furth rats (Harlan Sprague Dawley, Inc., Indianapolis, IN) between 2 and 3 mo of age.

1. Abbreviations used in this paper: Con A, concanavalin A; MHC, major histocompatibility complex.
Animals used in this study were maintained and used in accordance with recommendations in the Guide for the Care and Use of Laboratory Animals, prepared by the Institute of Laboratory Animal Resources, National Research Council (Department of Health, Education, and Welfare publication, National Institutes of Health 78-23, 1978), and guidelines of the Animal Care Advisory Committee of the University of Massachusetts Medical School, Worcester, MA.

Recipient rats. 121 male and female Wistar-Furth rats (Sprague Dawley) between 3 and 4 mo of age served as recipients. Recipient animals were all immunosuppressed with cyclophosphamide (see below). They were divided into four groups receiving one of the following treatments: 1) Con A-stimulated spleen cells from acute diabetic BB/W donor rats; 2) Con A-stimulated spleen cells from Wistar-Furth donor rats; 3) freshly isolated spleen cells (not Con A-stimulated) from acute diabetic BB/W donor rats; or 4) fresh RPMI medium alone.

Immunosuppression. Cyclophosphamide (Sigma Chemical Co., St. Louis, MO) was dissolved in sterile, isotonic saline. Recipient Wistar-Furth rats were injected intraperitoneally with doses of 100-150 mg/kg body wt 1-2 d before the injection of cells. This dosage range was chosen because it is effective in suppressing cell-mediated immune processes (16). Immunosuppressed rats were maintained on oxytetracycline (60 mg/dl, Terramycin; Pfizer Chemicals Div., Pfizer Inc., New York, NY) in hooded cages to reduce the likelihood of infection.

Glucose determinations and food consumption. From each of the four treatment groups, five recipient rats were killed by decapitation at 1, 3, and 5 wk (Table II). Glucose levels were determined on plasma collected from the heart in 1 ml of 10% EDTA solution. Food consumption was measured as described for the recipient rats.

Spleen cell culture. The cell culture procedure has been previously described (14). Briefly, spleens from acute diabetic BB/W and control Wistar-Furth rats were removed aseptically and teased apart in RPMI 1640 medium (Gibco Laboratories, Grand Island, NY) containing 10% heat-inactivated fetal calf serum (HyClone Laboratories, Sterile Systems, Inc., Logan, UT), 5 mM glutamine, 5 x 10^-5 M 2-mercaptoethanol, and 400 U/ml sodium penicillin. 100-300 x 10^6 cells were incubated in 150 ml RPMI 1640 containing 5 mg/ml Con A (Mile-Yeda, Rehovot, Israel). Incubations were carried out in flasks (Costar, Data Packaging Corp., Cambridge, MA) at 37°C in a humidified atmosphere of 5% CO2/95% air for 72 h. Cells were harvested by centrifugation, and the pellet was washed twice with serum-free RPMI 1640 medium. Cell numbers were determined using a Coulter Counter (Coulter Electronics Inc., Hialeah, FL). The cultured cells were injected into the tail veins of recipient animals using a 25-gauge needle with a cannula (Minitub 25; Deseret Co., Sandy, UT). Each recipient received one half the yield from a single spleen (~50-100 x 10^6 cells) in 1 ml of serum-free RPMI 1640 medium. Animals receiving freshly isolated cells were injected with similar numbers of cells. One group of control animals received 1 ml of serum-free RPMI medium without cells.

Morphology. Wistar-Furth recipients that became diabetic after administration of BB/W cells were killed at the time of onset of hyperglycemia to document the presence of insulitis. In addition, five control rats receiving Wistar-Furth cells and five moribund rats receiving high dose cyclophosphamide (150 mg/kg) were studied. Pancreatic tissue was fixed in Bouin's solution and embedded in paraffin. 5-10 µm sections were stained with hemotoxylin and eosin.

Statistics. Significant differences between experimental and control groups were determined using the Chi square test. A computer program (Minitab) was used for this purpose.

Results

Spleen cell culture

After 3 d in culture with Con A, blast cells, distinguished by their large size and regular spherical shape, were seen in all cultures. However, a greater percentage seemed to be present in cultures from Wistar-Furth compared with cultures from acute diabetic BB/W rats. The number of cells harvested from the BB/W cultures after 3 d ranged from ~30% lower to 10% higher than the initial count. On the other hand, the number of cells harvested from the control Wistar-Furth cultures fell within ±10% of the initial count.

Effects of cyclophosphamide treatment

Cyclophosphamide produced significant morbidity and mortality that was dose dependent. Approximately 50% of animals injected with a dose of 150 mg/kg died within 2 wk. Since in our previous study (14) we could not transfer diabetes in <7 d, those animals that died within 7 d after injection of cells (n = 3) were not included in our results.

Food consumption in animals treated with cyclophosphamide was markedly reduced. While the average consumption in untreated Wistar-Furth rats was 72.5±6.5 g (mean±SE)/d, that in cyclophosphamide-treated rats was 25.2±3.2 g/d.

Passive transfer

Rats receiving cells from acute diabetic BB/W donors. Freshly isolated spleen cells from acute diabetic rats, when injected into cyclophosphamide-treated Wistar-Furth recipients, did not result in hyperglycemia (Table I). Plasma glucose determinations during the 3 wk after the injection of cells never exceeded 136 mg/dl, and the average glucose concentration was 119±4 (mean±SE, n = 14 rats) at the time of sacrifice.

When Con A-stimulated spleen cells from acute diabetic BB/W donors were injected into cyclophosphamide-treated Wistar-Furth rats, hyperglycemia developed in 15% of the recipients (Table I). However, this occurred only in those rats receiving cyclophosphamide at a dose of 130 mg/kg or more. The mean interval from transfer to onset of hyperglycemia was 12±1 (SE) d, while the mean plasma glucose concentration from onset to sacrifice was 446±18 (SE) mg/dl (Table II). Plasma glucose concentrations were normal until onset, with a mean of 122±3 mg/dl 1-3 d before onset.

Control rats receiving Con A-stimulated Wistar-Furth spleen cells or RPMI media. Control rats receiving fresh RPMI media remained aglycosuric throughout the experiment and were killed 3-4 wk post injection of cells (Table I). Rats receiving Wistar-Furth spleen cells similarly remained aglycosuric and had a plasma glucose concentration of 121±2 mg/dl at sacrifice (Table I). Six of these animals had twice weekly plasma glucose determinations during the 30 d after injection of spleen cells. The highest value obtained was 151 mg/dl, and the average plasma glucose concentration was 122±2 mg/dl (mean±SE).

Morphology

Sections of pancreas from seven Wistar-Furth rats that became diabetic as the result of passive transfer revealed varying degrees of lymphocytic insulitis similar to that seen in spontaneously diabetic BB/W rats. Islets were distorted by the presence of numerous inflammatory cells permeating the interior and surrounding the periphery of the islets. Mononuclear cells were also seen around some ducts and small vessels. Pancreatic sections from Wistar-Furth recipients that received...
**Table I. Passive Transfer of Diabetes to Immunosuppressed Wistar-Furth Rats**

<table>
<thead>
<tr>
<th>Cyclophosphamide dose (mg/kg)</th>
<th>Number of recipient animals</th>
<th>Number becoming diabetic</th>
<th>Cyclophosphamide dose (mg/kg)</th>
<th>Number of animals receiving Wistar-Furth cells</th>
<th>Number of animals receiving BB/W cells</th>
<th>Number of animals receiving RPMI medium</th>
<th>Number becoming diabetic</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>10</td>
<td>0</td>
<td>100</td>
<td>6</td>
<td>0</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>125</td>
<td>4</td>
<td>0</td>
<td>130</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>130</td>
<td>4</td>
<td>2</td>
<td>135</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>135</td>
<td>14</td>
<td>1</td>
<td>140</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>140</td>
<td>3</td>
<td>0</td>
<td>150</td>
<td>15</td>
<td>14</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>150</td>
<td>33</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>68</strong></td>
<td><strong>10 (15%)</strong></td>
<td><strong>28</strong></td>
<td></td>
<td><strong>14</strong></td>
<td><strong>11</strong></td>
<td><strong>0</strong></td>
</tr>
</tbody>
</table>

* Significance compared with all 53 control animals, P < 0.001; control animals receiving Con A-stimulated Wistar-Furth cells, P < 0.05.

Plasma glucose concentrations in cyclophosphamide-treated control Wistar-Furth rats receiving Con A-stimulated Wistar-Furth cells or freshly isolated BB/W spleen cells were 121±2 and 119±4 mg/dl (mean±SE), respectively.

Wistar-Furth cells cultured with Con A appeared normal (n = 5). Sections from Wistar-Furth animals that received cyclophosphamide alone (150 mg/kg body wt) were also free of insulitis.

**Discussion**

The present data indicate that hyperglycemia and insulitis can be successfully transferred to the normal Wistar-Furth rat strain using Con A-stimulated spleen cells from acute diabetic BB/W donors. Con A-stimulated cells were used because our previous studies (14) suggested that freshly isolated spleen cells were ineffective in transferring diabetes. Indeed, this Con A requirement was confirmed by our inability to transfer diabetes into immunosuppressed Wistar-Furth recipients of freshly isolated acute diabetic spleen cells. It also proved necessary to immunosuppress recipients with high doses of cyclophosphamide for effective transfer of diabetes. In addition to minor histoincompatibilities between Wistar-Furth and BB/W rats, suppressor cells in Wistar-Furth recipients could interfere with the activity of the transferred cells. Indeed, a deficiency in suppressor cells (17) has been proposed as a contributing factor in the spontaneous expression of diabetes in BB/W rats. Cyclophosphamide was chosen for immunosuppression because it inhibits T lymphocyte subsets, including suppressor cells (16).

There was a significant mortality associated with the use of high doses of cyclophosphamide. Furthermore, diminished food intake showed that even animals that survived were not in ideal health. Blood glucose values (not shown) of moribund immunosuppressed rats at sacrifice, however, were normal. In addition, pancreatic morphology was normal, with no evidence of insulitis. Furthermore, plasma glucose concentrations in control rats receiving Con A-stimulated Wistar-Furth or freshly isolated acute diabetic BB/W spleen cells remained normal throughout the experiment. Overall, this model was useful to answer the questions addressed, but it is not entirely satisfactory for routine study. Interestingly, like et al. recently found (18) that transfer of diabetes from acute diabetic BB/W donors to inbred diabetes-resistant BB/W rats (W-line) required the use of 150 mg/kg cyclophosphamide. Strains with diabetes genes bred into defined inbred backgrounds should overcome the problem of requiring high doses of cyclophosphamide.

An important question to be answered regards the specific cell type or types responsible for transfer. Specific T cell subset antibodies can be used for transfer when the aforementioned congenic lines are available. Since the MHC-restricted cytotoxic T lymphocyte is one possible candidate for the ultimated effector cell, passive transfer experiments using recipient strains...
that do not share the RT1<sup>+</sup> MHC of the BB rat may provide important information needed to answer this question.

Studies of islet transplants to BB rats (9) are also relevant to this question. Recent results of Weringer and Like (19) show insulitis in isolated islets from various non-MHC compatible strains when these islets are transplanted under the renal capsule of diabetic BB/W rats. Since these animals retained a BB/W diabetic pancreas and had incompatible tissue grafts, it cannot be definitively concluded that the insulitis seen was associated with the beta cell cytotoxicity that leads to spontaneous diabetes. Preliminary results from our laboratory suggest an inability to transfer diabetes into the non-MHC compatible New England Deaconess Hospital strain (RT1<sup>+</sup>) (20) (n = 24).

Transfer studies using rats immunosuppressed with agents that obliterate all T cells could be useful in determining whether the immune cells responsible for beta cell destruction are present in the donor inoculum, or whether endogenous T cells need to be recruited. Similarly, studies of T cell lines developed from diabetic rats may be useful in this regard.

Acknowledgment

We thank Kathy Meunier for her skillful technical assistance. Dr. Koervy is the recipient of a postdoctoral fellowship from the Juvenile Diabetes Foundation.

This work was supported in part by National Institutes of Health grants AM30846, AM32520, and AM26733.

References


